Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]
Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) in adult patients. The approval from the European Commission (EC) is for the combination of ADCETRIS with CHP (cyclophosphamide, doxorubicin, prednisone. It comes in the wake of a […]
Continue reading …PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status
February 20, 2020 No Comment
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation from the US Food and Drug Administration (FDA) in first-line advanced bladder cancer. The FDA breakthrough therapy status for PADCEV, KEYTRUDA combination is for the treatment […]
Continue reading …Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer
December 19, 2019 No Comment
Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) for the treatment of advanced urothelial cancer, the most common form of bladder cancer. Padcev, which has been co-developed by the two pharma companies, is a Nectin-4-directed antibody and microtubule […]
Continue reading …
ADCETRIS EC approval : The European Commission (EC) has expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to cover treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adult patients. ADCETRIS is an antibody-drug conjugate (ADC) that targets CD30, which is a defining marker of […]
Continue reading …Seattle Genetics’ Adcetris gets FDA approval for peripheral T-cell lymphoma
November 18, 2018 No Comment
Adcetris FDA approval : Seattle Genetics has secured new approval from the US Food and Drug Administration (FDA) for its monoclonal antibody Adcetris (brentuximab vedotin), which is in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) for the treatment of certain types of peripheral T-cell lymphoma (PTCL). Adcetris FDA approval for PTCL in combination with CHP […]
Continue reading …
Business News Today
- Boxlight acquires AV solutions provider Sahara Presentation System
- SSGT II acquires two self storage facilities near Tampa, Florida
- Preferred Apartment Communities to sell student housing portfolio to TREP
- Corbion, Total to build €200m PLA bioplastics plant in France
- iPipeline acquires Impact Financial Systems
- Nautilus Solar Energy acquires 17MW solar portfolio from Pine Gate Renewables
- Palladium Equity Partners acquires majority stake in Trachte USA from MPE Partners
- The Hilb Group acquires life and health agency Ganim Benefits in Connecticut
- La Brea Bakery to invest in automation processes at Van Nuys bakery
- REG begins construction on single wind turbine project in Minnesota
